Nobody dares stopping clinical research, not even COVID-19
Descripción general
Resumen del artículo
This study describes how a single company adapted its clinical trial operations during the first nine months of the COVID-19 pandemic, implementing measures like remote monitoring and telehealth visits. The limited scope to one company and relatively short timeframe are major limitations, restricting the generalizability of the findings.
Explícamelo como si tuviera cinco años
This paper describes how one company managed its ongoing clinical trials during the initial phase of the COVID-19 pandemic. They made changes like remote monitoring and virtual visits to keep trials going.
Posibles conflictos de intereses
Several authors are employed by MEDSIR, the company whose practices are the subject of the study. Additionally, several authors disclose financial ties to pharmaceutical companies.
Limitaciones identificadas
Explicación de la calificación
This is a descriptive study with limited generalizability, providing a snapshot of one company's experience. While it offers valuable insights into adaptations made during a challenging time, its scope and methodology prevent a higher rating. The disclosed conflicts of interest also contribute to the lower rating.
Conviene saber
Este es el análisis de Starter. Paperzilla Pro verifica cada cita, investiga los antecedentes de los autores y las fuentes de financiación, y utiliza razonamiento avanzado con IA para ofrecer información más exhaustiva.
Explorar Pro →